

Testing the mHealth app SyD to improve the physical and mental wellbeing of UK healthcare workers

Submission date 14/03/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 12/04/2023	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 13/06/2023	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Preventable diseases like heart disease, diabetes, and joint problems can make people sick and reduce their quality of life. Mental health problems like stress, anxiety, and depression affect a lot of people too. The COVID-19 pandemic has made things worse. People may have trouble following lifestyle changes to improve their health, but things like self-monitoring and goal-setting can help. Using mobile health (mHealth) interventions, like an app called SYD, can personalize recommendations to help people make these changes. We want to see if using SYD can improve people's quality of life and mental health.

Who can participate?

Active NHS staff with an NHS email address, aged at least 18 years, own a smartphone, Hospital Anxiety and Depression Scale (HADS) test score between 8 and 14 inclusive, indicating mild to moderate anxiety or depressive symptoms

What does the study involve?

As part of the study you will be asked to:

1. Engage with the SYD application on your smartphone
2. Complete study assessments involving questions regarding your quality of life and wellbeing using a study website

What are the possible benefits and risks of participating?

Potential participants who score between 8-14 inclusive will be eligible, as these scores indicate individuals most likely to benefit from interventions of wellbeing like SYD and to be considered safe as higher scores may indicate depression/anxiety levels needing formal psychological evaluation.

We do not anticipate there being any risk associated with participating in this study. All information provided on the SYD app is intended for general information and educational purposes only, not as medical advice or a substitute for medical advice provided by a doctor or other qualified health practitioner.

Where is the study run from?
Southern Health NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
December 2020 to March 2022

Who is funding the study?
iamYiam (UK)

Who is the main contact?
Prof Shanaya Rathod, shanayarathod@nhs.net
Sana Sajid, Sana.Sajid@southernhealth.nhs.uk

Contact information

Type(s)
Scientific

Contact name
Dr Peter Phiri

ORCID ID
<https://orcid.org/0000-0001-9950-3254>

Contact details
Moorgreen Hospital
Botley Road
Southampton
United Kingdom
SO30 3JB
+44 7557541943
peter.phiri@southernhealth.nhs.uk

Type(s)
Principal investigator

Contact name
Prof Shanaya Rathod

Contact details
Research and Development
Clinical Trials Facility
Tom Rudd Unit Moorgreen Hospital
Southampton
United Kingdom
SO30 3JB
+44 2380 47 5112
shanaya.Rathod@southernhealth.nhs.uk

Type(s)
Scientific

Contact name

Dr Pedro Henriques

Contact details

iamYiam

Floor 3

207 Regent Street

London

United Kingdom

W1B 3HH

-

pedro.henriques@iamyiam.com

Type(s)

Public

Contact name

Ms Sana Sajid

Contact details

Research & Innovation Department

Southern Health NHS Foundation Trust

Tom Rudd Unit

Moorgreen Hospital

Botley Rd

West End

Southampton

United Kingdom

SO30 3JB

-

Sana.Sajid@southernhealth.nhs.uk

Additional identifiers**Clinical Trials Information System (CTIS)**

Nil known

Integrated Research Application System (IRAS)

294071

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 294071, CPMS 48382

Study information**Scientific Title**

Randomised controlled trial of the mHealth app SyD to improve the physical and mental wellbeing of UK healthcare workers

Study objectives

To quantify the change in Quality of Life (QOL) following an intervention with SYD, a personalised preventive mHealth partner. Measures of mental health (stress, anxiety and depression) will also be tracked as a way to assess the wellbeing potential of this non-clinical intervention.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 15/02/2021, HRA and Health Care Research Wales (Health and Care Research Wales Support and Delivery Centre, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, UK; +44 2920 230457; healthandcareresearch@wales.nhs.uk), ref: 21/HRA/0308

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Mental health (anxiety, depression, stress), quality of life

Interventions

The trial is designed carefully and deliberately to fully and prospectively elucidate all elements of comparison of the impact of SYD.

Participants would be randomly assigned to one of the two trials cohorts (PHE, 2020).

For cohort one, the study allows data collection as part of a 'Before and After Study', with SYD as the intervention provided to participants, to engage with, for 3 months as a minimum. Additionally, by having a further cohort (cohort two) without SYD being engaged for the first 3 months, the study allows 'Case Controlled' cross comparisons between the two cohorts. Additionally, by collecting data on the first cohort further to 6 months, we can review persistence of effects from 3 to 6 months of SYD and whether participants voluntarily continue using SYD or not beyond the primary endpoint.

Bringing on board the second cohort to have SYD switched on after 3 months, allows a comparison within this cohort 'Before and After' at a different time-point to the switch on for cohort one. This allows for any effects of SYD to be evaluated as COVID-19 levels themselves change over time.

Meanwhile comparing the two cohorts after the second cohort is exposed to SYD will allow comparisons of an early (in second cohort) versus a more experienced group (first cohort) using SYD contemporaneously.

Intervention Group: Participants in the Intervention Group will be asked to complete baseline assessments (Month 0) and download / interact with the SYD app (Months 0-3). Participants will complete monthly assessments for a period of 3 months (Months 1-3) to analyse the primary endpoint. A final assessment will be performed at Month 6, to monitor longer term effects of the intervention.

Control Group: Participants in the Control Group will be asked to complete baseline assessments (Month 0) and monthly assessments (Months 1-3) to provide control data in a comparable population

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

SyD app

Primary outcome(s)

1. WHO Quality of Life-BREF (WHOQOL-BREF) survey assessed global quality of life in the Control and Intervention group at Baseline, Month 1, 2, 3 & 6
2. EuroQoL EQ-5D-5L assessed Health-related quality of life in the Control and Intervention group at Baseline, Month 1, 2, 3 & 6

Key secondary outcome(s)

1. Perceived Stress Scale (PSS-4) was used for the Control and Intervention group at Baseline, Month 1, 2, 3 & 6
2. Hospital Anxiety and Depression Scale (HADS) was used for the Control and Intervention group at Baseline, Month 1, 2, 3 & 6

Completion date

31/03/2022

Eligibility

Key inclusion criteria

1. NHS staff with an NHS email address which can be used for this study
2. Age \geq 18 years
3. Own a personal smartphone device (iOS or Android-based) which can be used for this study
4. Sufficient English language ability to familiarise themselves with and engage with SYD and study assessments
5. Hospital Anxiety and Depression Scale (HADS) test score between 8 and 14 inclusive, indicating mild to moderate anxiety or depressive symptoms
6. Provision of informed consent

Participant type(s)

Health professional

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

595

Key exclusion criteria

1. Unwilling or unable to participate
2. Any other concurrent psychological interventions
3. Concurrent participation in an interventional clinical trial
4. People considered clinically extremely vulnerable from COVID-19: <https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19>)

Date of first enrolment

01/06/2021

Date of final enrolment

15/04/2022

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Moorgreen Hospital

Botley Road

West End

Southampton

United Kingdom

SO30 3JB

Sponsor information

Organisation

Southern Health NHS Foundation Trust

ROR

<https://ror.org/03qesm017>

Funder(s)

Funder type

Industry

Funder Name

iamYiam

Results and Publications

Individual participant data (IPD) sharing plan

Data will not be shared with anyone outside of the Sponsor and iamYiam research project teams, unless needed to independently verify results at the request of regulators.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		13/06/2023	13/06/2023	No	No
Participant information sheet	version 1.8	26/10/2021	29/03/2023	No	Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file	version 2.0	13/04/2022	29/03/2023	No	No